FindTrial
Sign In

Develop and evaluate breathhold black blood magnetic resonance imaging technology for simultaneous acquisition of quantitative T1rho and its composite metric for early diagnosis of liver fibrosis

Develop and evaluate breathhold black blood magnetic resonance imaging technology for simultaneous acquisition of quantitative T1rho and its composite metric for early diagnosis of liver fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022012
Enrollment
Unknown
Registered
2019-03-20
Start date
2019-03-21
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver fibrosis

Interventions

Gold Standard:A standard multi-slice T2 MRI
Index test:breathhold&#32
black&#32
blood&#32
magnetic&#32
resonance&#32
imaging&#32
technology

Sponsors

The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Between aged 18 to 55 years; Informed written consent obtained.

Exclusion criteria

Exclusion criteria: Contraindications to MRI such as the presence of metallic implants, claustrophobia and pregnancy

Design outcomes

Primary

MeasureTime frame
diagnostic value of the proposed MR imaging technology for detecting early stage liver fibrosis;—

Secondary

MeasureTime frame
feasibility of this pulse sequence for routine clinical use;—

Countries

China

Contacts

Public ContactWeitian Chen

The Chinese University of Hong Kong

wtchen@cuhk.edu.hk+852 35056000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026